Moxifloxacin: safety profile
The latest, so-called respiratory, fluoroquinolones are a group of antimicrobial agents (AMA), most commonly prescribed for community-acquired lower respiratory tract infection (caLRTI), which is a relevant issue in routine clinical practice.
Päätekijä: | A. I. Sinopalnikov |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | Russian |
Julkaistu: |
Remedium Group LLC
2013-12-01
|
Sarja: | Медицинский совет |
Aiheet: | |
Linkit: | https://www.med-sovet.pro/jour/article/view/1152 |
Samankaltaisia teoksia
-
Community-acquired pneumonia against a background of chronic heart failure: diagnosis and treatment
Tekijä: A. A. Bobylev, et al.
Julkaistu: (2014-12-01) -
Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new?
Tekijä: A. I. Sinopalnikov
Julkaistu: (2014-12-01) -
Rational therapy of patients with lower respiratory tract infections
Tekijä: V. A. Kazantsev
Julkaistu: (2013-12-01) -
Cough in children as a symptom of respiratory tract infections: a new look at the problem of antibiotic therapy
Tekijä: O. A. Egorova
Julkaistu: (2014-12-01) -
Местная иммуномодуляция при заболеваниях верхних дыхательных путей
Julkaistu: (2018-06-01)